Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cardiovascular

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1757974

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1757974

Antithrombotic Drugs

PUBLISHED:
PAGES: 282 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Antithrombotic Drugs Market to Reach US$75.9 Billion by 2030

The global market for Antithrombotic Drugs estimated at US$51.4 Billion in the year 2024, is expected to reach US$75.9 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Oral Route, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$49.5 Billion by the end of the analysis period. Growth in the Injectable Route segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$14.0 Billion While China is Forecast to Grow at 10.8% CAGR

The Antithrombotic Drugs market in the U.S. is estimated at US$14.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$16.0 Billion by the year 2030 trailing a CAGR of 10.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Antithrombotic Drugs Market - Key Trends & Drivers Summarized

Why Are Antithrombotic Drugs Crucial in the Modern Management of Cardiovascular and Thrombotic Disorders?

Antithrombotic drugs have become an indispensable part of contemporary medicine, particularly in the prevention and treatment of thromboembolic disorders, which are among the leading causes of morbidity and mortality worldwide. These drugs-which include anticoagulants, antiplatelet agents, and fibrinolytics-are widely used to prevent blood clots in high-risk populations such as patients with atrial fibrillation, deep vein thrombosis (DVT), pulmonary embolism, and those who have undergone surgeries like hip replacement or heart valve implantation. With the global rise in cardiovascular diseases (CVDs), driven by sedentary lifestyles, obesity, hypertension, and diabetes, the demand for effective thrombosis prevention is higher than ever. Antithrombotics are also vital in managing acute conditions such as myocardial infarction and ischemic stroke, where timely clot prevention or dissolution can be life-saving. Their role in long-term secondary prevention strategies ensures that patients who have already experienced clotting events remain protected from recurrence. Moreover, increasing awareness among both healthcare providers and patients about the risks of clot formation has led to broader and more proactive prescribing patterns. Clinical guidelines from leading health authorities now recommend antithrombotic therapy as a standard of care for numerous indications, reinforcing their medical necessity. As populations age and comorbidities become more common, the patient base eligible for antithrombotic therapy continues to expand, underscoring the drugs’ critical role in both acute and chronic care models globally.

How Are Scientific and Pharmaceutical Advances Improving the Safety and Efficacy of Antithrombotic Therapies?

Significant strides in pharmacology and drug development have led to the evolution of safer, more effective, and more patient-friendly antithrombotic therapies. While traditional agents such as warfarin and heparin have long been mainstays of anticoagulant therapy, they present challenges like narrow therapeutic windows, frequent monitoring, and dietary or drug interactions. In response, a new generation of antithrombotic drugs-particularly direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, edoxaban, and dabigatran-has revolutionized the field. These agents offer predictable pharmacokinetics, fixed dosing, and reduced need for routine blood testing, significantly improving patient adherence and quality of life. Advanced antiplatelet agents like prasugrel and ticagrelor have demonstrated superior outcomes in certain high-risk cardiovascular settings compared to older drugs like clopidogrel. Additionally, pharmaceutical research is increasingly focused on developing reversible agents and antidotes that enhance safety during emergency situations or surgeries. For example, idarucizumab and andexanet alfa are now approved as reversal agents for DOACs, addressing earlier concerns about bleeding risks. Nanotechnology and targeted drug delivery systems are being explored to optimize the localization and controlled release of antithrombotic agents, minimizing systemic exposure and reducing side effects. Furthermore, combination therapies tailored to patient-specific risk profiles are gaining attention, supported by advances in pharmacogenomics and real-world data analytics. These scientific developments are not only expanding the range of therapeutic options but are also enabling more personalized and precise treatment protocols, reshaping how clinicians approach thrombotic risk management.

How Are Demographic and Clinical Trends Shaping the Growing Demand for Antithrombotic Drugs?

The rising global burden of chronic conditions and aging populations is playing a pivotal role in shaping the antithrombotic drugs market. Older adults are significantly more susceptible to thrombotic events due to vascular aging, reduced mobility, and higher prevalence of conditions like atrial fibrillation and venous thromboembolism. This demographic trend alone has created a steadily expanding patient pool in need of both preventive and curative antithrombotic therapy. Additionally, the increased detection and diagnosis of cardiovascular diseases through advanced imaging, routine screenings, and wearable health technologies have contributed to earlier initiation of treatment protocols that include antithrombotics. The globalization of Western diets and sedentary lifestyles has led to a sharp rise in diabetes, obesity, and hypertension in emerging economies, further boosting demand in regions previously considered low-risk. Surgical practices have also evolved to include more minimally invasive procedures, organ transplants, and cancer treatments-all of which can increase thrombotic risk and require prophylactic antithrombotic therapy. In oncology, for example, cancer-associated thrombosis is now recognized as a significant complication, prompting routine antithrombotic use in certain patient populations. Furthermore, the COVID-19 pandemic highlighted the association between severe viral infections and coagulopathy, leading to wider use of anticoagulants in hospitalized patients and raising awareness of thrombotic risks beyond traditional indications. This convergence of demographic and clinical factors is creating sustained, global demand for antithrombotic drugs, compelling healthcare systems to enhance access and optimize guidelines for their rational use.

What Are the Key Drivers Behind the Global Expansion of the Antithrombotic Drugs Market?

The growth in the antithrombotic drugs market is driven by a synergy of medical, technological, regulatory, and economic factors that are reshaping cardiovascular and hematological care across the globe. One of the most powerful drivers is the global epidemiological transition toward non-communicable diseases, particularly cardiovascular disorders, which account for a significant share of global mortality. The development and widespread acceptance of DOACs have transformed the market landscape by offering safer, more convenient alternatives to traditional anticoagulants, thereby expanding both patient compliance and clinical applications. Regulatory approvals for newer agents, supported by robust clinical trial data and fast-track mechanisms, have accelerated market penetration in multiple regions. Additionally, expanded healthcare infrastructure in developing countries is enabling greater access to life-saving drugs, including antithrombotics, often supported by government-sponsored insurance programs and public health initiatives. The pharmaceutical industry’s investment in R&D, including the pursuit of next-generation agents with reduced bleeding risk, continues to fuel innovation. Telemedicine and digital health technologies are also contributing by facilitating remote monitoring of patients on antithrombotic therapy, improving adherence and safety. Another key driver is the integration of antithrombotic treatment into standardized care pathways for conditions such as stroke prevention in atrial fibrillation, postoperative thromboprophylaxis, and long-term secondary prevention of cardiovascular events. Academic collaborations, increased physician education, and heightened public awareness campaigns are further elevating the market profile. Combined, these drivers are generating strong and sustained growth in the global antithrombotic drugs market, ensuring its continued expansion across both mature and emerging healthcare economies.

SCOPE OF STUDY:

The report analyzes the Antithrombotic Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Administration Route (Oral Route, Injectable Route); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • Abbott Laboratories
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Daiichi Sankyo
  • Eli Lilly and Company
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • Medtronic
  • Mylan (now part of Viatris)
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Servier
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical
  • Teva Pharmaceutical
  • UCB

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP36180

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Antithrombotic Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Burden of Cardiovascular and Thromboembolic Events Throws the Spotlight on Antithrombotics
    • Use in Stroke, DVT, PE, and Post-Operative Prevention Supports High Clinical Adoption
    • OEMs Offering Novel Oral Anticoagulants (NOACs) Improve Patient Compliance and Risk Profiles
    • Expansion of Indications Across Atrial Fibrillation and Cancer-Associated Thrombosis Drives Volume
    • OEM Innovation in Fixed-Dose, Low-Monitoring Drugs Enhances Outpatient Management
    • Growing Demand for Antiplatelet Agents in Secondary Prevention Enhances Therapeutic Breadth
    • Use of D-Dimer Testing and Diagnostic Algorithms Supports Risk Stratification and Timely Initiation
    • Focus on Rapid-Onset and Short Half-Life Drugs Address Surgical Bridging Needs
    • Use in Geriatric Populations With Polypharmacy Concerns Drives Development of Safer Alternatives
    • Growth in Extended Prophylaxis in Orthopedic and Cancer Surgery Enhances Institutional Use
    • OEM Investment in Combination Anticoagulant-Antiplatelet Regimens Expands Therapeutic Efficacy
    • Increased Digital Health Integration for Dosing Support and Monitoring Adds Patient Management Value
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antithrombotic Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antithrombotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antithrombotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Antithrombotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Injectable Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Injectable Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Injectable Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • JAPAN
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • CHINA
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • EUROPE
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Antithrombotic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Antithrombotic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Antithrombotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • FRANCE
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • GERMANY
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Antithrombotic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Antithrombotic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Antithrombotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • INDIA
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Antithrombotic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Antithrombotic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Antithrombotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Antithrombotic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Antithrombotic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Antithrombotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030
  • AFRICA
    • Antithrombotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Antithrombotic Drugs by Administration Route - Oral Route and Injectable Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Antithrombotic Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Injectable Route for the Years 2014, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Antithrombotic Drugs by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Antithrombotic Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!